Markus Rüegg studied biochemistry at the University of Zurich and graduated with a PhD in the field of Neurobiology.

In 1989 he went as a postdoctoral fellow to conduct research at the Department of Neurobiology at Stanford University School of Medicine.

Since 1998 he is a Professor of Neurobiology and teaches and conducts research at the Biozentrum of the University of Basel.

SEAL Therapeutics Ltd. aims to develop a gene therapy for the severe LAMA2-related muscular dystrophy (LAMA2 MD).

[6] Rüegg studies the molecular principles that are essential for the development and the maintenance of the neuromuscular system.